- AU$125.58m
- AU$113.30m
- AU$27.57m
- 56
- 36
- 40
- 42
Annual income statement for Cyclopharm, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14.7 | 17.8 | 25 | 27.8 | 27.6 |
| Cost of Revenue | |||||
| Gross Profit | 10.7 | 12.8 | 17.5 | 17.5 | 17.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 20.3 | 22.1 | 30.7 | 31.7 | 41 |
| Operating Profit | -5.64 | -4.26 | -5.76 | -3.97 | -13.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.84 | -4.35 | -6.03 | -4.19 | -13.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.04 | -5.04 | -6.61 | -4.7 | -13.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.04 | -5.04 | -6.61 | -4.7 | -13.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.04 | -5.04 | -6.61 | -4.7 | -13.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.083 | -0.056 | -0.072 | -0.082 | -0.128 |
| Dividends per Share |